INCY
$94.22
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Recent News
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer
Earlier this month, Incyte reported that the European Commission approved Zynyz (retifanlimab) plus platinum-based chemotherapy for first-line treatment of advanced squamous cell carcinoma of the anal canal, supported by Phase 3 POD1UM-303/InterAACT2 data showing improved progression-free survival and no new safety signals. This second European indication for Zynyz broadens Incyte’s immuno-oncology footprint and underscores how well-executed late-stage trials can translate into meaningful...
2 Value Stocks to Consider Right Now and 1 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.